James R. Glidewell Dental Ceramics, doing business as Glidewell Laboratories, has signed a licensing agreement with Technique d'usinage Sinlab (Sinlab), pursuant to which, the latter granted the former and its affiliates a non-exclusive worldwide license to its patented US inventions.
Glidewell can make use, sell, offer to sell, and import Sinlab’s patented US inventions including patents relating to its Technobar and Technoguide technologies, under the terms of the deal.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
In a series C venture financing round led by Acre Venture Partners, synthetic biology diagnostic company, Sample6 has raised gross proceeds of $12.7m, which will be used to commercialise its food pathogen detection system.
The round has also seen the participation of new investor Valley Oak Investments and existing investors Canaan Partners and Cultivian Sandbox Venture Partners.
To advance the development of its rapid Zika tests, point-of-care diagnostic tests developer, OraSure Technologies has been awarded a contract from the U.S. Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response’s Biomedical Advanced Research and Development Authority (BARDA).
The six-year, multi-phased contract, which includes a total funding of $16.6m, comprises an initial commitment of $7m and options for additional funding of up to $9.6m for further product enhancements, and clinical and regulatory activities.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataWireless medical technology company, BioTelemetry, and digital health company, Bloom Technologies, have entered an agreement to commercialise the former’s consumer oriented prenatal health sensor.
Pursuant to the agreement, the latter will pay the former a percentage of revenue to license and commercialise the latter’s proprietary telemetry technology, which will improve the level of treatment to expectant mothers by providing a wide variety of pre-natal data for healthcare providers.
In a series C financing round led by Ion Beam Applications, laser-based proton therapy systems developer, HIL Applied Medical, has raised gross proceeds of $2m, which will be used to further advance its laser-based proton therapy systems.
Also participated in the financing round were the company’s existing investors from previous rounds and OurCrowd, a crowd funding platform.
